The diabetes vaccine Diamyd® shows continued positive clinical course after 30 months
Positive effects such as lower insulin requirements and improved blood glucose levels are observed for the first four diabetes patients that have been followed for 30 months in the DIAGNODE-1 trial. Safety looks good and no serious side effects have been reported.In a fifth interim report from the open label investigator initiated clinical pilot trial DIAGNODE-1, where the diabetes vaccine Diamyd® is administered directly into the lymph node, results are presented for the first four patients that have been followed for the entire study period, 30 months. No serious side effects have been